ReviewAnnals of gastroenterological surgery2018
Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center.
Review in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review.Frontiers in oncology · 2022Pooled it
- Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.Liver cancer · 2026Review
- Long-term survival outcome of portal vein embolization in patients with perihilar cholangiocarcinoma: a retrospective cohort study.World journal of surgical oncology · 2025Article
- [Advances in minimally invasive surgical techniques for liver transplant recipients].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Article
- AI-based digital histopathology for perihilar cholangiocarcinoma: A step, not a jump.Journal of pathology informatics · 2024Article
- Outcome of patients with perihilar cholangiocarcinoma and previous biliary instrumentation: an observational study.BMC gastroenterology · 2024Observational
- Dynamic three-dimensional liver volume assessment of liver regeneration in hilar cholangiocarcinoma patients undergoing hemi-hepatectomy.Frontiers in oncology · 2024Article
- Robotic Hepatectomy plus Biliary Reconstruction for Bismuth Type III and Type IV Hilar Cholangiocarcinoma: State of the Art and Literature Review.Journal of personalized medicine · 2023Review
- Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.Cancers · 2023Review
- Article
- Lymph Node Staging in Perihilar Cholangiocarcinoma: The Key to the Big Picture.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant.Langenbeck's archives of surgery · 2023Article
- New Imaging Techniques.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2023Article
- Evaluation of the short-term outcomes of robotic-assisted radical resection for perihilar cholangiocarcinoma: a propensity-scored matching analysis.Gastroenterology report · 2023Article
- Article
- Locoregional Approaches in Cholangiocarcinoma Treatment.Cancers · 2022Review
- Preoperative Management of Perihilar Cholangiocarcinoma.Cancers · 2022Review
- Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hilar cholangiocarcinoma, which represents approximately 60% of biliary tract malignancies, is increasing in incidence and presents an ongoing challenge for patients and hepatobiliary surgeons. Although the majority of patients present with advanced disease, the remaining minority of patients are best treated with surgical resection or transplant. Transplant is typically reserved for locally unresectable tumors often in the setting of underlying hepatic dysfunction and will not be discussed herein. This review, therefore, focuses on oncological resection and the strategies implemented for the treatment of hilar cholangiocarcinoma at a quaternary referral center, including preoperative considerations such as patient selection and optimization of the future liver remnant, nuances to the operative approach for these tumors such as resection under low central venous pressure and management of the bile duct, as well as postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.